TY - JOUR
T1 - Sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913)
T2 - Toxicity and bone marrow radioprotection
AU - Mendiondo, Oscar A.
AU - Connor, Andrew M.
AU - Grigsby, Perry
N1 - Funding Information:
Presented at the CROS Conference on Chemical Modification: Radiation and Cytotoxic Drugs, Key Biscayne, Florida September 17-20, 198 I. Supported in part by NIH Center Grant CA 177 186.
PY - 1982
Y1 - 1982
N2 - Experiments have been carried out to compare the toxicity and radioprotective effect of sodium hydrogen-S-(3-amino-2-hy(iroxypropyl) phosphorothioate (WR-77913) with those of S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721). The drugs were given intraperitoneally to 12 week-old female BALB/c mice 30 minutes before whole body irradiation. Lethality at 30 days was the endpoint used. The drug LD 50 30 was 678 mg/kg for WR-2721 and 3574 mg/kg for WR-77913. The LD 50 30 for WR-77913 combined with 500 mg/kg of WR-2721 was 3328 mg/kg. The LD 50 30 for misonidazole was 380 mg/kg when given in combination with 500 mg/kg of WR-2721 and 801 mg/kg when combined with 2200 mg/kg of WR-77913. Protection of bone marrow by WR-77913 and WR-2721 was comparable at doses close to the maximum tolerable dose (MTD, drug dose lethal to 10% of the animals at 30 days), but W R-77913 gave better protection at 25% of the MTD. These characteristics of low toxicity, non-additive toxicity with WR-2721, less toxicity in combination with misonidazole and adequate bone marrow protection at 25`,0 of the MTD, make WR-77913 a protector worthy of further investigation.
AB - Experiments have been carried out to compare the toxicity and radioprotective effect of sodium hydrogen-S-(3-amino-2-hy(iroxypropyl) phosphorothioate (WR-77913) with those of S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721). The drugs were given intraperitoneally to 12 week-old female BALB/c mice 30 minutes before whole body irradiation. Lethality at 30 days was the endpoint used. The drug LD 50 30 was 678 mg/kg for WR-2721 and 3574 mg/kg for WR-77913. The LD 50 30 for WR-77913 combined with 500 mg/kg of WR-2721 was 3328 mg/kg. The LD 50 30 for misonidazole was 380 mg/kg when given in combination with 500 mg/kg of WR-2721 and 801 mg/kg when combined with 2200 mg/kg of WR-77913. Protection of bone marrow by WR-77913 and WR-2721 was comparable at doses close to the maximum tolerable dose (MTD, drug dose lethal to 10% of the animals at 30 days), but W R-77913 gave better protection at 25% of the MTD. These characteristics of low toxicity, non-additive toxicity with WR-2721, less toxicity in combination with misonidazole and adequate bone marrow protection at 25`,0 of the MTD, make WR-77913 a protector worthy of further investigation.
KW - Misonidazole
KW - Radioprotectors
KW - WR-2721
KW - WR-77913
UR - https://www.scopus.com/pages/publications/0019965439
U2 - 10.1016/0360-3016(82)90682-4
DO - 10.1016/0360-3016(82)90682-4
M3 - Article
C2 - 6286552
AN - SCOPUS:0019965439
SN - 0360-3016
VL - 8
SP - 553
EP - 555
JO - International journal of radiation oncology, biology, physics
JF - International journal of radiation oncology, biology, physics
IS - 3-4
ER -